Compare
Actinium Pharmaceuticals, Inc. vs iBio, Inc. vs Inovio Pharmaceuticals, Inc. vs Connect Biopharma Holdings Ltd
| Latest fiscal year | Actinium Pharmaceuticals, Inc. ATNM | iBio, Inc. IBIO | Inovio Pharmaceuticals, Inc. INO | Connect Biopharma Holdings Ltd CNTB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $90.0K | $100.0K | $65.3K | $64.0K |
| Revenue growth (YoY) | n/a | -75.0% | -70.0% | -99.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$33.89M | -$33.04M | -$84.95M | -$55.48M |
| EPS (Diluted) | -$1.09 | -$0.32 | -$1.81 | -$1.00 |
| Operating cash flow | -$24.58M | -$23.22M | -$88.63M | -$51.21M |
| Free cash flow | -$24.68M | -$23.80M | -$88.92M | -$51.64M |
| Cash & equivalents | $48.00M | $56.40M | $44.27M | $38.34M |
| Total assets | $51.77M | $99.11M | $74.31M | $56.08M |
| Total liabilities | $43.94M | $13.40M | $50.21M | $14.10M |
| Shareholders' equity | $7.83M | $85.71M | $24.10M | $41.98M |
| Return on year-end equity | -432.6% | -38.6% | -352.5% | -132.2% |
| Shares outstanding | 31.20M | 55.70M | 69.00M | 56.44M |
Revenue, most recent five fiscal years
| Fiscal year | Actinium Pharmaceuticals, Inc. | iBio, Inc. | Inovio Pharmaceuticals, Inc. | Connect Biopharma Holdings Ltd |
|---|---|---|---|---|
| Latest | $90.0K Ended 2025-12-31 | $100.0K Ended 2026-06-30 | $65.3K Ended 2025-12-31 | $64.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $400.0K Ended 2025-06-30 | $217.8K Ended 2024-12-31 | $26.03M Ended 2024-12-31 |
| 2 years earlier | $81.0K Ended 2023-12-31 | $225.0K Ended 2024-06-30 | $832.0K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $1.03M Ended 2022-12-31 | $0 Ended 2023-06-30 | $10.26M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.14M Ended 2021-12-31 | $1.88M Ended 2022-06-30 | $1.77M Ended 2021-12-31 | n/a |